These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 15377314

  • 21. Botulinum toxin in migraine prophylaxis.
    Göbel H.
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [Abstract] [Full Text] [Related]

  • 22. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
    Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW.
    Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
    [Abstract] [Full Text] [Related]

  • 23. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

  • 24. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group.
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M.
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [Abstract] [Full Text] [Related]

  • 29. Botulinum toxin A for the treatment of delayed gastric emptying.
    Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB.
    Am J Gastroenterol; 2008 Feb; 103(2):416-23. PubMed ID: 18070232
    [Abstract] [Full Text] [Related]

  • 30. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
    Dodick D, Blumenfeld A, Silberstein SD.
    Clin Dermatol; 2004 Feb; 22(1):76-81. PubMed ID: 15158549
    [Abstract] [Full Text] [Related]

  • 31. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
    Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S, Byrd S.
    Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
    [Abstract] [Full Text] [Related]

  • 32. Role of botulinum toxin type A in the prophylactic treatment of migraine headaches.
    Chilson CN, Brown SJ.
    Ann Pharmacother; 2005 Dec; 39(12):2081-5. PubMed ID: 16264063
    [Abstract] [Full Text] [Related]

  • 33. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group.
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [Abstract] [Full Text] [Related]

  • 34. Botulinum toxin type A for migraine. First, do no harm.
    Prescrire Int; 2011 Dec; 20(122):287-90. PubMed ID: 22216539
    [Abstract] [Full Text] [Related]

  • 35. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ, AEGIS Investigator Study Group.
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [Abstract] [Full Text] [Related]

  • 36. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
    Kudrow D, Thomas HM, Ruoff G, Ishkanian G, Sands G, Le VH, Brown MT.
    Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
    [Abstract] [Full Text] [Related]

  • 37. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK, Rozen TD, Kori SH, Shrewsbury SB.
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [Abstract] [Full Text] [Related]

  • 38. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group.
    Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
    [Abstract] [Full Text] [Related]

  • 39. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
    Carroll A, Barnes M, Comiskey C.
    Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
    [Abstract] [Full Text] [Related]

  • 40. Botulinum toxin type A (BOTOX) for treatment of migraine.
    Binder WJ, Brin MF, Blitzer A, Pogoda JM.
    Semin Cutan Med Surg; 2001 Jun; 20(2):93-100. PubMed ID: 11474749
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.